Inhibition of RAS-targeted prenylation: protein farnesyl transferase inhibitors revisited
Section snippets
Background and introduction
The 1990s were to be the era for exploiting the earlier advances in molecular oncology which had greatly increased our understanding of certain genetic events that were associated with the propensity for uncontrolled proliferation leading to tumourigenesis. Such knowledge had opened up potentially exploitable targets for anti-cancer drug development-one of which was the ras oncogene and its 21 kD protein product, Ras. The knowledge that Ras was readily prenylated by protein farnesyl transferase
Increasing complexity of the ras signalling pathway
Ras comprises a family of GTP-dependent proteins (G-proteins) that are localised at the inner surface of the cell membrane and participate in transmitting signals for growth and many other processes from the outside to the inside of the cell [11], [12], [13].
These G-proteins cycle between a GTP-binding active ‘ON’ state and a GDP-binding inactive ‘OFF’ state. The biological activity of Ras is controlled by a regulated GDP/GTP cycle. Guanine nucleotide exchange factors (GEFs; RasGRF 1 / 2 and
Initial characterisation of PFTase inhibitors
Inevitably the first screen for PFTase inhibitors involves their evaluation in direct enzyme assays, initially H-Ras was commonly used, and literature reports abound now with examples citing IC50 values in nanomolar or even subnanomolar ranges. The next stage requires an evaluation of their ability to inhibit Ras processing in whole cells and again experimenters generally favoured H-Ras overexpressing cells. Due to poor cell permeability and instability, compounds frequently have lost 2–3 logs
Perspectives and conclusions
The question as to how these novel prenyltransferase inhibitors might best be used clinically is crucial to their subsequent development, not only in the clinical setting itself, but also in their preclinical development study design. Realistically, on the present evidence, with the current generation of PFTase and GGTase I inhibitors, their successful use in cancer therapy as single agents is highly unlikely. Thus we are left to consider the question of their usage in combinations and here it
Reviewers
Dr François F. Lavelle, Rhône-Poulenc Rorer, Centre de Recherche de Vitry-Alfortville, 13, quai Jules Guesde, F-94403 Vitry-sur-Seine, France.
Dr Serge Halazy, Department of Chemistry Serono Pharmaceutical Research Institute, CH-1228 Plan-les-Ouates, Switzerland.
Professor Gilles Favre, Scientific Director, Centre de Lutte contre le Cancer Claudius Regaud, Université Paul Sabatier, 20–24, rue du pont Saint Pierre, F-31052 Toulouse, France.
Dr Bridget T Hill PhD, EurChem, FRSC, FIBiol, graduated from the University of London obtaining her doctorate in Biochemistry before gaining post-doctoral experience in London, Philadelphia (USA) and Toronto (Canada). She returned to the ICRF Laboratories, London (UK) and as Head of Cellular Chemotherapy researched fundamental drug resistance mechanisms and collaborated in clinical studies devising new therapies for cancers of the head and neck and breast. In 1993 she moved to direct cancer
References (94)
Introduction to signal transduction
Biochem. Pharmacol.
(1998)Ras-like GTPases
Biochim. Biophys. Acta
(1997)- et al.
Increasing complexity of the Ras signaling pathway
J. Biol. Chem.
(1998) - et al.
Expression of ras proto-oncogenes: regulation and implications in the development of human tumors
Crit. Rev. Oncol/Hematol.
(1997) - et al.
Protein prenyltransferases
J. Biol. Chem.
(1996) - et al.
The Ras-related protein Rheb is farnesylated and antagonizes Ras signaling and transformation
J. Biol. Chem.
(1997) - et al.
Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras
Biochim. Biophys. Acta
(1997) - et al.
Inhibition of ras prenylation:a novel approach to cancer chemotherapy
Pharmacol. Ther.
(1997) - et al.
Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltranferase I inhibitor
J. Biol. Chem.
(1995) - et al.
A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells
J. Biol. Chem.
(1998)
Polylysine and CVIM sequences of K-RasB dictate specificity of preylation and confer resistance to benzodiazepine peptidomimetics in vitro
J. Biol. Chem.
Characterization of Ha-Ras, N-Ras, Ki-Ras4A and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I
J. Biol. Chem.
K- and N-Ras are geranylated in cells treated with farnesyl protein transferase inhibitors
J. Biol. Chem.
Platelet-derived growth factor receptor tyrosine phosphoylation requires protein geranylgeranylation but not farnesylation
J. Biol. Chem.
The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors
J. Biol. Chem.
The geranyl-geranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SD11) in a p53-independant manner
J. Biol. Chem.
Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB
J. Biol. Chem.
Innovative treatment programs against cancer. I Ras oncoprotein as a molecular target
Biochem. Pharmacol.
A phase I and pharmacologic study of the farnesyl protein transferase (FPT) inhibitor SCH 66336 in patients with locally advanced or metastatic cancer
Proc. Am. Soc. Clin. Oncol.
The farnesyl protein transferase (FPTase) inhibitor L-778123 in patients with solid cancers
Proc. Am. Soc. Clin. Oncol.
Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule
Proc. Am. Soc. Clin. Oncol.
Phase I and pharmacokinetic study of SCH666336, a novel FPTI, using a 2-week on, 2-week off schedule
Proc. Am. Soc. Clin. Oncol.
A phase I and pharmacokinetic study of farnesyltransferase inhibitor, R115777, in advanced cancer
Proc. Am. Soc. Clin. Oncol.
Oncoprotein networks
Cell
Increasing complexity of ras signalling
Oncogene
Signaling pathways in Ras-mediated tumorigenicity and metastasis
Proc. Natl. Acad. Sci. USA
Function and regulation of Ras
Annu. Rev. Biochem.
The Ras superfamily of GTPases
FASEB J.
The GTPase superfamily: a conserved switch for diverse cell functions
Nature
Ras farnesyltransferase: a new therapeutic target
J. Med. Chem.
Caught in the act of the switch-on
Nature
Oncogenic activation of ras proteins. GTPases in Biology I
Farnesyltransferase inhibitors versus Ras inhibitors
Curr. Opinion. Chem. Biol.
Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation
Proc. Natl. Acad. Sci. USA
Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity
Proc. Natl. Acad. Sci. USA
Activation of Rac1, RhoA and mitogen-activated protein kinases is required for Ras transformation
Mol. Cell. Biol.
An essential role for Rac in Ras transformation
Nature
A role for Rho in Ras transformation
Proc. Natl. Acad. Sci. USA
Protein prenylation et cetera:signal transduction in two dimensions
Science
Protein isoprenylation and methylation at carboxy-terminal cysteine residues
Annu. Rev. Biochem.
Protein prenylation:molecular mechanisms and functional consequences
Ann. Rev. Biochem.
Inhibitors of the Ras signal transduction pathway as potential antitumour agents
J. Enzyme. Inhib.
Rationally designed FPTase inhibitors
Drugs Future
Inhibitors of protein farnesylation
Exp. Opin. Ther. Patents
American Association for Cancer Research 1998; promises and prospects for the next century
Exp. Opin. Invest. Drugs
Phase I trial of farnesyl-transferase inhibitor, R115777, in advanced cancer
Proc. Am. Assoc. Cancer. Res.
Cited by (0)
Dr Bridget T Hill PhD, EurChem, FRSC, FIBiol, graduated from the University of London obtaining her doctorate in Biochemistry before gaining post-doctoral experience in London, Philadelphia (USA) and Toronto (Canada). She returned to the ICRF Laboratories, London (UK) and as Head of Cellular Chemotherapy researched fundamental drug resistance mechanisms and collaborated in clinical studies devising new therapies for cancers of the head and neck and breast. In 1993 she moved to direct cancer research at CRPF, Castres, France, concentrating on new drug discovery, with a current interest in PFTase inhibitors.